Effect of purslane extract on non-alcoholic fatty liver disease

Phase 3

• Conditions: onalcoholic fatty liver disease.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT201701172709N44
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

Being volunteer or Wishing to attend
Age 18 years or older
Alanine aminotransferase (ALT) greater than 19 IU/L for women and greater than 30 IU/L for men
Evidence of fatty liver in ultrasonography with a score of 1 or more
BMI: 20-40 kg/m2

Exclusion Criteria

Other acute or chronic hepatic disorders (hepatitis B or C)
Biliary diseases
Cancer
Hypertension
History of cardiovascular disease
Nephrolithiasis (oxalate stones) or history of oxalate stones
Consumption of omega-3 and vitamin E supplement
Alcohol use
Use of hepatotoxic medications during last month
Changing medication dosage during the study
Pregnancy
Lactation
Compliacne less than 80%

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alanine aminotransferase (ALT). Timepoint: At the begining and at the end of week 12. Method of measurement: Laboratory kit.;Aspartate aminotransferase (AST). Timepoint: At the begining and at the end of week 12. Method of measurement: Laboratory kit.